SCHEMBL26801765

SCHEMBL26801765

Cc1ccc(C(=O)N[C@H]2CC[C@H](N(C)c3ccc(C#N)c(Cl)c3)CC2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 4/20 0.74
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ LMNA P02545 1/20 0.41
▸ ADRA2A P08913 2/20 0.40
▸ HRH1 P35367 2/20 0.40
▸ HTR2B P41595 2/20 0.40
▸ MCHR1 Q99705 2/20 0.40
▸ S1PR3 Q99500 3/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ S1PR2 O95136 1/20 0.39
▸ S1PR4 O95977 1/20 0.39
▸ S1PR1 P21453 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ GRM5 P41594 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27295127 0.91 AR (0.73) ARNPC1RAB9ACYP1A2CYP2C19
SCHEMBL26801788 0.91 AR (0.61) ARNPC1RAB9AHPGDCYP1A2
SCHEMBL24031267 0.90 AR (0.71) ARNPC1RAB9AADRA2AHRH1
SCHEMBL26801770 0.88 AR (0.66) ARADRA2AHRH1HTR2BMCHR1
SCHEMBL26801776 0.87 AR (0.58) ARNPC1RAB9AHPGDCYP1A2
SCHEMBL26801782 0.87 AR (0.58) ARNPC1RAB9AHPGDCYP1A2
SCHEMBL26801774 0.87 AR (0.65) ARADRA2AHRH1HTR2BMCHR1
SCHEMBL26119571 0.87 AR (0.64) ARPGRCYP2D6CYP2C9
SCHEMBL26119568 0.87 AR (0.64) ARPGRCYP2D6CYP2C9
SCHEMBL27027590 0.86 AR (0.59) ARNPC1RAB9AS1PR3S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023242598-A1 BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2023-12-21 — — WO disclosed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 — — US disclosed
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND UNIV MICHIGAN REGENTS (US) 2023-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357249-A1 ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND AR, GPER1, CRBN AR 1/4885NPC1 1026/4885RAB9A 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback